Teva, Sanofi announce accelerated timeline for duvakitug program

Teva (TEVA) and Sanofi (SNY) announced an update to the timing for the anti-TL1A, duvakitug program investigating the human IgG1-A2 monoclonal antibody targeting TL1A for moderate-to-severe IBD. Patient enrollment in the RELIEVE UCCD Phase 2b trial has completed early due to significant acceleration in patient recruitment. As a result, Teva and Sanofi now anticipate having topline results for both UC and CD in Q4 and detailed results will be presented in a scientific forum in 2025. This adjustment replaces the previously planned interim analysis for the second half of 2024, which will not be conducted. Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients